Cancer is a disease driven by genetic variation and mutation. Exome sequencing can be
utilized for discovering these variants and mutations across hundreds of tumors. Here we …

Background The full complement of DNA mutations that are responsible for the pathogenesis
of acute myeloid leukemia (AML) is not yet known. Methods We used massively parallel …

Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse,
which is associated with clonal evolution at the cytogenetic level 1 , 2 . To determine the …

Background The genetic alterations responsible for an adverse outcome in most patients
with acute myeloid leukemia (AML) are unknown. Methods Using massively parallel DNA …

Determining the genetic basis of cancer requires comprehensive analyses of large collections
of histopathologically well-classified primary tumours. Here we report the results of a …

Most mutations in cancer genomes are thought to be acquired after the initiating event,
which may cause genomic instability and drive clonal evolution. However, for acute myeloid …

Massively parallel sequencing technologies hold incredible promise for the study of DNA
sequence variation, particularly the identification of variants affecting human disease. The …

Acute myeloid leukaemia is a highly malignant haematopoietic tumour that affects about
13,000 adults in the United States each year. The treatment of this disease has changed little in …

Cancer immunoediting, the process by which the immune system controls tumour outgrowth
and shapes tumour immunogenicity, is comprised of three phases: elimination, equilibrium …

Massively parallel DNA sequencing technologies provide an unprecedented ability to
screen entire genomes for genetic changes associated with tumour progression. Here we …